Features of protocols of assisted reproductive technologies in patients of the older age group depending on the ovarian stimulation drug: recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropins
https://doi.org/10.21518/2079-701X-2022-16-16-29-34
Abstract
Introduction. An actual task of reproductive medicine is a comparative analysis of the use of highly purified urinary gonadotropins and recombinant FSH preparations for ovarian stimulation in in vitro fertilization programms in older patients. This was suggested on the basis of data available in the literature on the possible positive effect of LH on the effectiveness of various stages of ART programs in this category of women.
Aim. To compare the parameters of ovarian stimulation, gametogenesis, early embryogenesis, pregnancy rate (PRF) in patients of older reproductive age in ART programs who underwent ovarian stimulation using drugs containing FSH + LH or drugs containing recombinant FSH.
Materials and methods. The study included 44 patients aged 35 to 40 years with infertility due to tubal- peritoneal and non-severe male factor treated with ART techniques. In 50% of patients, ovarian stimulation was performed with highly purified urinary gonadotropin, in 50 % – with rFSH preparations.
Results. The characteristics of the embryological stage in both groups showed high rates, comparable with global data. The frequency of pregnancy and early miscarriage was comparable in both groups.
Conclusions. Ovarian stimulation with MHT is effective, safe and can be recommended for patients of older reproductive age.
About the Author
E. E. Kraevaya
Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
Elizaveta E. Kraevaya, Cand. Sci. (Med.), Researcher
Department of Assistive Technologies in the Treatment of Infertility named after Professor B. V. Leonov
117997
4, Academician Oparin St.
Moscow
References
1. Корсак В.С., Долгушина Н.В., Корнеева И.В., Колода Ю.А., Смирнова А.А., Аншина М.Б. и др. Женское бесплодие: клинические рекомендации. М.; 2021. 50 c. Режим доступа: https://moniiag.ru/wp-content/uploads/2019/07/Klinicheskie-rekomendatsii.-ZHenskoe-besplodie.pdf. Korsak V.S., Dolgushina N.V., Korneeva I.V., Koloda Yu.A., Smirnova A.A., Anshina M.B. et al. Female infertility: clinical guidelines. Moscow; 2021. 59 p. (In Russ.) Available at: https://moniiag.ru/wp-content/uploads/2019/07/Klinicheskie-rekomendatsii.-ZHenskoe-besplodie.pdf.
2. Кузьмичев Л. Н. Вспомогательные репродуктивные технологии в лечении бесплодия у женщин позднего репродуктивного периода / Л. Н. Кузьмичев [и др.] // АГИнфо. – 2009. – (4): 25–28. Режим доступа: http://www.ag-info.ru/files/aginfo/2009-4/aginfo-09-04-05.pdf. – Kuzmichev L. N., Nazarenko T. A., Mikaelyan V. G., Mishieva N. G. Assisted reproductive technologies in the treatment of infertility in women of the late reproductive period. AGInfo. 2009; (4): 25–28. (In Russ.) Available at: http://www.ag-info.ru/files/aginfo/2009-4/aginfo-09-04-05.pdf.
3. Ермоленко К. С. Новые пути решения проблемы бесплодия в старшем репродуктивном возрасте / К. С. Ермоленко [и др.] // Вестник Российского университета дружбы народов. Серия: Медицина. – 2013. – (S5): 130–136. Режим доступа: https://journals.rudn.ru/medicine/article/view/3441. – Ermolenko K. S., Gagaev C. G., Soloveva A. V., Rapoport S. I. New ways to overcome infertility problem in women of advanced reproductive age. RUDN Journal of Medicine. 2013; (S5): 130–136. (In Russ.) Available at: https://journals.rudn.ru/medicine/article/view/3441.
4. Урюпина К. В. Яичниковый фактор бесплодия у пациенток позднего репродуктивного возраста / К. В. Урюпина [и др.] // Медицинский вестник Юга России. – 2020. – 11 (1): 14–20. https://doi.org/10.21886/2219-8075-2020-11-1-14-20. – Uryupina K. V., Kutsenko I. I., Kravtsova E. I., Gavryuchenko P. A. Ovarian infertility factor in patients of late reproductive age. Medical Herald of the South of Russia. 2020; 11 (1): 14–20. (In Russ.) https://doi.org/10.21886/2219-8075-2020-11-1-14-20.
5. Mochtar M. H., Danhof N. A., Ayeleke R. O., Van der Veen F., van Wely M. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. Cochrane Database Syst Rev. 2017 4; 5 (5): CD005070. https://doi.org/10.1002/14651858.CD005070.pub3.
6. Alviggi C., Conforti A., Esteves S. C., Andersen C. Y., Bosch E., Bühler K. et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018; 109 (4): 644–664. https://doi.org/10.1016/j.fertnstert.2018.01.003.
7. Bosch E., Broer S., Griesinger G., Grynberg M., Humaidan P., Kolibianakis E. et al. ESHRE guideline: ovarian stimulation for IVF / ICSI. Hum Reprod Open. 2020; (2): hoaa009. https://doi.org/10.1093/hropen/hoaa009.
8. Hompes P. G. A., Broekmans F. J., Hoozemans D. A., Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008; 89 (6): 1685–1693. https://doi.org/10.1016/j.fertnstert.2007.05.039.
9. Gardner D. K., Weissman A., Howles C. M., Shoham Z. (eds.). Textbook of Assisted Reproductive Technologies: Laboratory and Clinical Perspectives (Reproductive Medicine and Asst. Reproduction). 3 rd ed. London: Informa healthcare; 2009. 1004 p.
10. Сыркашева А. Г. Бесплодие у женщин старшего репродуктивного возраста: причины, тактика ведения, перспективы использования преимплантационного генетического скрининга (обзор литературы) / F/ U/ Сыркашева, Е. О. Ильина, Н. В. Долгушина // Гинекология. – 2016. – 18 (3): 40–43. Режим доступа: https://omnidoctor.ru/upload/iblock/480/48019a0623fa5df140b10325c4a3f903.pdf. – Syrkasheva A. G., Ilina E. O., Dolgushina N. V. Infertility in women of advanced age: etiology, management, application of preimplantation genetic screening. Gynecology. 2016; 18 (3): 40–43. (In Russ.) Available at: https://omnidoctor.ru/upload/iblock/480/48019a0623fa5df140b10325c4a3f903.pdf.
11. Жабченко И. А. Особенности фертильности у женщин старшего репродуктивного возраста: проблемы отложенного деторождения и методы их коррекции / И. А. Жабченко, О. Р. Сюдмак // Репродуктивная медицина. – 2019. – (3): 29–36. Режим доступа: https://repromed.kz/index.php/journal/article/view/108. – Zhabchenko I. A., Syudmak O. R. Features of fertility in women of older reproductive age: problems of delayed childbearing and methods for their correction. Reproductive Medicine. 2019;(3): 29–36. (In Russ.) Available at: https://repromed.kz/index.php/journal/article/view/108.
12. Platteau P., Andersen A. N., Balen A., Devroey P., Sørensen P., Helmgaard L., Arce J. C. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006; 21 (7): 1798–804. https://doi.org/10.1093/humrep/del085.
13. Fleming R., Chung C. C., Yates R. W., Coutts J. R. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod. 1996; 11 (9): 1854–1858. https://doi.org/10.1093/oxfordjournals.humrep.a019506.
14. Van Wely M., Westergaard L. G., Bossuyt P. M., Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003;(1): CD003973. https://doi.org/10.1002/14651858.CD003973.
15. Weghofer A., Munné S., Brannath W., Chen S., Tomkin G., Cekleniak N. et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod. 2008; 23 (3): 499–503. https://doi.org/10.1093/humrep/dem412.
16. Yang P. K., Wu M. Y., Chao K. H., Chang C. H., Chen M. J., Chen S. U. Lower rate of early pregnancy loss in patients experiencing early-onset low LH in GnRH antagonist cycles supplemented with menotropin. J Formos Med Assoc. 2019; 118 (1 Pt 1): 92–98. https://doi.org/10.1016/j.jfma.2018.01.012.
Review
For citations:
Kraevaya EE. Features of protocols of assisted reproductive technologies in patients of the older age group depending on the ovarian stimulation drug: recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropins. Meditsinskiy sovet = Medical Council. 2022;(16):29-34. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-16-29-34
Views:
336
Email this article 